FBR Reiterates Bullish View on Aurinia (AUPH) as Data Supports Strong Potential in Lupus Nephritis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Shares jump on tech boost; fragile yen on intervention watch
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices steady after rallying on US stock decline, business data
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Hasbro (HAS) brand strength sees earnings top expectations
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Tesla, AT&T, Biogen and Hasbro rise premarket; Uber, Enphase fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Aurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates over Time for Voclosporin in the Treatment of Lupus Nephritis
October 6, 2016 8:00 AM EDT
- Complete remission rates increase to 70% in the open-label study at
24 weeks
-Patients in remission at eight weeks remained in
remission at 24 weeks
-Data presented at the 10th
Annual European Lupus Meeting
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia... More
